why choose us

First received: April 06, 2023

Clinical Trial: Enablers and Barriers to Hydroxyurea Use for Sickle Cell Disease Jamaica

Study Status: Completed

Recruit Status: RECRUITING

Condition: Sickle Cell Disease

Study Type: OBSERVATIONAL


Official Title: Access to Care for SCD Management in Jamaica: Enablers and Barriers to Hydroxyurea Utilization

Brief Summary: Sickle cell disease (SCD) is associated with a lifetime of medical and socio-behavioural complications that require coordination of care from multidisciplinary teams.Access to adequate care for SCD is important as inadequate access can contribute to increased acute care utilization, disjointed care delivery, and earlier mortality for many SCD patients.Hydroxyurea (HU) is the first drug approved for the treatment of SCD and improves many adverse outcomes of SCD and yet its use remains sub-optimal.This mixed-methods…

Read more